In arm A, 57% and 43% of patients carried deleterious BRCA1 and BRCA2 mutations, respectively; 56% and 44% had triple-negative and HR+ disease; and 59% had more than two tumor sites (liver metastasis, 52%; CNS metastasis, 6%). This evidence concerns the gene BRCA2 and neoplasm.